社区

Suzhou, July 10, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that after receiving the designation for its in-house developed KX-826 from the International Nomenclature Cosmetic Ingredient (the “INCI”), the Company’s cosmetics with KX-826 as the main ingredient was officially launched into the international market recently. The first product is the topical anti-hair loss solution for androgenetic alopecia (the “AGA”). 

The Company will further explore the efficacy of KX-826 in the field of AGA and acne, actively enrich the product lines, increase market promotion to target users and meet customer requirements under different usage scenarios. The Company is of the view that the launch of the New Product will provide a solid stream of revenue and cash flow to the Group, benefiting the Group as a whole in the long term.

KX-826 is one of the core innovative products of the Group. During the course of its development, it has been used to complete multiple clinical trials for the treatment of male and female AGA in China and the United States. It has demonstrated excellent safety profile and remarkable therapeutic effects in anti-hair loss and new hair growth.

Dr. Youzhi Tong, the founder, chairman and CEO of Kintor Pharma, said,"The launch of the New Product is the first commercialization attempt of KX-826 in the field of dermatology, representing the Group’s transition from R&D stage to commercialization stage. Going forward, the Company will further commercialize its cosmetics products worldwide, providing more convenient and effective products to consumers with the demand of anti-hair loss and new hair growth. In the future, the Group plans to allocate more resources to enhance the Group’s commercialization capabilities to boost brand awareness, capture market dynamics and increase the penetration rate of the products."

About Kintor Pharmaceutical Limited

Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas. After several years' development, the Company has developed diverse product pipeline built on dermatology and oncology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of six products under clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.